Clinical Trials (Phase IV)

Found 3,377 articles

• 

  Your Feedback Matters! Topics in 2019

  1/15/2019

  As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.

• Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference

  12/31/2018

  Company to provide first-look at preclinical and clinical portfolio

• Imfinzi demonstrates clinical activity in Stage IV, 1st-line non-small cell lung cancer in Phase III MYSTIC trial

  12/13/2018

  AstraZeneca and MedImmune, its global biologics research and development arm, have presented overall survival (OS) and progression-free survival (PFS) data from the Phase III MYSTIC trial at the European Society for Medical Oncology (ESMO) Immuno-Oncology 2018 Congress in Geneva, Switzerland.

• At ASH, Extended Half-Life Therapies ELOCTATE® and ALPROLIX® Demonstrate Proven Efficacy and Well-Characterized Safety over Four Years

  12/1/2018

  Bioverativ Inc., a Sanofi company, and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in hemophilia.

• GTI launches new website at www.gti.energy

  11/19/2018

  GTI is proud to unveil our new website, which features a streamlined design with enhanced navigation.

• Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33RD Annual Meeting

  11/6/2018

  Personalis, Inc. will present new data at the upcoming Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, taking place in Washington, D.C., November 9-11, 2018.

• 

  Half of U.K. Clinical Trials Fail to Publish Data, Report Shows

  11/1/2018

  The United Kingdom is calling for greater clinical trial transparency after a government committee released a report that indicates that data from about half of all clinical trials in that country are not published, raising concerns over research integrity and risks to human health.

• Eagle Pharmaceuticals Announces Results of Study for Fulvestrant

  10/30/2018

  Analysis of data shows fulvestrant did not meet bioequivalence criteria

• First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis

  10/26/2018

  Mallinckrodt plc today confirmed screening of the first patient in the company's Phase 4, multi-center, multiple-dose, open label study to assess the effects of H.P. Acthar Gel as a therapy option in patients with Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU).

• Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting

  10/22/2018

  Phase 4 study interim analysis showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity at 12 weeks

• See More, Simply, in Microsurgery

  10/7/2018

  Leica Microsystems introduces new PROVIDO multidisciplinary surgical microscope at leading otolaryngology conference in Atlanta

• Acerus Announces Publication of Manuscript Reporting Early Data from Partner-Sponsored Natesto® Spermatogenesis Study

  9/17/2018

  Early Data Suggests Sperm Concentration, Motility, and Total Motile Sperm Count Remain Within Normal Ranges in Hypogonadal Men Taking Natesto®

• New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety

  9/17/2018

  - INPULSIS®-ON study indicates safety and efficacy of Ofev® (nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS trials

• Dallas-Based Software Developer, DoctorLogic®, Makes the 2018 Inc. 5000 List

  8/21/2018

  DoctorLogic ranks 317 out of 5,000 fastest-growing private companies with a total growth of more than 1,500% since its launch.

• Lafayette General Medical Center Unveils Xenex LightStrike Germ-Zapping Robots

  8/7/2018

  New technology destroys deadly pathogens and bacteria lurking on hospital surfaces

• Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®

  7/17/2018

  BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients

• 

  National Academies Report: Provide Patients with Clinical Study Results

  7/12/2018

  A report recently published by the National Academies of Sciences, Engineering, and Medicine concluded that institutions and researchers should regularly and carefully evaluate whether and how to provide study results to participants.

• Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)

  7/3/2018

  Cannabics Pharmaceuticals Inc. announced that it has concluded its clinical trial held at Rambam Medical Center.

• PQ Bypass Reports Positive 12-Month Results for Entirely New Procedure to Treat Extremely Long SFA Lesions in Patients with PAD

  6/28/2018

  DETOUR I Trial Presented during SVS Vascular Annual Meeting 2018 Late Breaking Clinical Trial Session

• WCG (WIRB-Copernicus Group) Clinical Services Division Partners with InformedDNA to Help Sponsors Design and Execute More Effective Clinical Trials

  6/25/2018

  Companies join forces to deliver new solutions that optimize genetics in clinical trials in the era of precision medicine.